Provided by Tiger Fintech (Singapore) Pte. Ltd.

IDEAYA Biosciences

26.92
-0.5700-2.07%
Post-market: 26.920.00000.00%16:20 EDT
Volume:682.36K
Turnover:18.44M
Market Cap:2.36B
PE:-7.11
High:27.65
Open:27.65
Low:26.77
Close:27.49
52wk High:32.67
52wk Low:13.45
Shares:87.64M
Float Shares:81.82M
Volume Ratio:0.63
T/O Rate:0.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7869
EPS(LYR):-3.3605
ROE:-35.09%
ROA:-23.84%
PB:2.46
PE(LYR):-8.01

Loading ...

BRIEF-IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Reuters
·
Sep 26

IDEAYA Biosciences Announces New Inducement Stock Option Grants for Newly Hired Employee Under 2023 Incentive Plan

Reuters
·
Sep 26

IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Sep 26

Promising Developments in IDEAYA Biosciences’ Pipeline Drive Buy Rating with $74 Price Target by 2026

TIPRANKS
·
Sep 25

UBS Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)

TIPRANKS
·
Sep 24

IDEAYA Biosciences Initiated at Buy by Guggenheim

Dow Jones
·
Sep 18

Ideaya Biosciences initiated with a Buy at Guggenheim

TIPRANKS
·
Sep 18

Buying IDEAYA Might Be The Wrong IDYA Right Now

Benzinga_recent_news
·
Sep 16

Mizuho Lifts Price Target on IDEAYA Biosciences to $44 From $43, Keeps Outperform Rating

MT Newswires Live
·
Sep 12

IDEAYA Biosciences: Promising Clinical Developments and Strategic Positioning Highlighted by Buy Rating

TIPRANKS
·
Sep 12

IDEAYA Biosciences Inc : Leerink Partners Raises Target Price to $30 From $27

THOMSON REUTERS
·
Sep 09

RBC Capital Adjusts Price Target on IDEAYA Biosciences to $38 From $36, Maintains Outperform, Speculative Risk

MT Newswires Live
·
Sep 09

BUZZ-U.S. STOCKS ON THE MOVE-Sanofi SA, Nutanix, Bullish

Reuters
·
Sep 08

IDEAYA Biosciences Is Maintained at Market Outperform by JMP Securities

Dow Jones
·
Sep 08

Ideaya Reports 'Positive' Initial Data on Trodelvy Combination Trial in Urothelial Cancer

MT Newswires Live
·
Sep 08

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Amid Rate-Cut Hopes, Soft Data

MT Newswires Live
·
Sep 08

BRIEF-IDEAYA Reports Positive Phase 1/2 Data for IDE397 + Trodelvy in MTAP-Deleted Urothelial Cancer

Reuters
·
Sep 08

IDEAYA Biosciences Inc - Manageable Safety Profile in Ide397 and Trodelvy Trial

THOMSON REUTERS
·
Sep 08

IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of Ide397, a Potential First-in-Class Mat2a Inhibitor, and Trodelvy® in Mtap-Deletion Urothelial Cancer

THOMSON REUTERS
·
Sep 08

BUZZ-U.S. STOCKS ON THE MOVE-Veeva, Gold miners, Ideaya Biosciences

Reuters
·
Sep 08